Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Trends Endocrinol Metab TEM
Published 2020 Feb 27
Some studies suggest it may improve cardiac function and reduce symptoms of angina
Key findings from animal studies Superior body weight reduction compared to GLP-1 monoagonists in diet-induced obese rodent models Significant reduction in hepatic fat content in NASH models, suggesting relevance for metabolic liver disease research Improvements in lipid profiles (triglycerides, LDL cholesterol) beyond what was observed with GLP-1 monoagonism alone Evidence of increased energy expenditure supporting the glucagon receptor-mediated thermogenesis hypothesis Clinical Research Timeline (Updated Through 2026) Retatrutide has now progressed through Phase 3 clinical trials with three major readouts between December 2025 and May 2026, representing the most advanced clinical development of any triple hormone receptor agonist to date
